Cytosorbents Advances DrugSorb-ATR Amid FDA Review Challenges and Potential Market Pathway

Cytosorbents Advances DrugSorb-ATR Amid FDA Review Process

CytoSorbents Corporation, a key player in blood purification technologies, provides an important update regarding its DrugSorb™-ATR device, aimed at improving outcomes for patients undergoing urgent coronary artery bypass graft (CABG) surgery. Recently, the U.S. Food and Drug Administration (FDA) upheld a previous De Novo denial of the device but clarified that no safety issues were identified in the review process. This decision follows an appeal that began with a denial letter issued on April 25, 2025, and continued through a July meeting with FDA officials, where the agency indicated that additional data is necessary to support the device's intended use. The FDA has outlined a pathway for potential market authorization, prompting CytoSorbents to actively engage in discussions to better understand these requirements.

Despite the disappointment over the upheld denial, CytoSorbents CEO Dr. Phillip Chan remains optimistic about the progress made in addressing the FDA's concerns. He emphasizes that the DrugSorb-ATR has demonstrated a favorable benefit-to-risk profile, affirming its safety for patients. This device is particularly significant for heart attack patients on ticagrelor, who are at high risk for perioperative complications, including severe bleeding or delays in surgery. The need for a reliable solution in this context is critical, as thousands of patients undergo CABG procedures annually in the U.S., often facing challenges that affect their surgical outcomes.

In light of the latest FDA communications, CytoSorbents is also considering the option for further appeal available to the Director of the Center for Devices and Radiologic Health (CDRH). This strategic move underscores the company's commitment to collaborating with the FDA to refine the device's approval pathway. By working closely with regulatory bodies, CytoSorbents aims to navigate the complexities of the approval process and ultimately deliver an innovative solution that addresses the pressing needs of patients requiring urgent surgical interventions.

In addition to the developments surrounding DrugSorb-ATR, CytoSorbents continues to position itself at the forefront of blood purification technologies. The company’s focus on improving patient outcomes in critical care settings aligns with ongoing trends in healthcare that prioritize safety and efficacy. As discussions with the FDA progress, the broader implications of these advancements resonate within the industry, highlighting the essential role of regulatory collaborations in fostering innovation.